-
公开(公告)号：US07317014B2
公开(公告)日：2008-01-08
申请号：US10469647
申请日：2003-07-21
IPC分类号： C07D239/30 , C07D239/48 , A61K31/505
CPC分类号： C07D239/30 , C07D239/36 , C07D239/38 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/56
摘要： The present invention relates to novel derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrimidine derivatives of the general formula (I)
摘要翻译： 本发明涉及通式（I）的新衍生物，其衍生物，其类似物，其互变异构形式，它们的立体异构体，其多晶型物，它们的水合物，它们的溶剂化物，其药学上可接受的盐和含有它们的药学上可接受的组合物。 本发明更具体地提供了通式（I）的新型嘧啶衍生物，
-
公开(公告)号：US20110034413A1
公开(公告)日：2011-02-10
申请号：US12676709
申请日：2008-08-08
申请人： Narendra Shriram Joshi , Pawan Aggarwal , Vitthalbhai Ketan Hirpara , Manu Jaggi , Anu Singh , Anshumali Awasthi , Ritu Verma
发明人： Narendra Shriram Joshi , Pawan Aggarwal , Vitthalbhai Ketan Hirpara , Manu Jaggi , Anu Singh , Anshumali Awasthi , Ritu Verma
IPC分类号： A61K31/7008 , C07D311/30 , C07H5/06 , A61K31/352 , A61P35/00
CPC分类号： C07D311/30
摘要： The present invention provides novel Quercetin derivatives of formula (I) and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1 is hydrogen, benzyl or substituted benzyl; R2 is hydrogen, benzyl or substituted benzyl, linear or branched (C1-C6) alkyl, substituted alkyl, aryl, substituted aryl, heterocycle and substituted heterocycle, useful for treatment of various disorders including cancer, multi-drug resistant cancers, viral infections etc. The invention also provides a process for the preparation of compounds of formula (I) and pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供新的式（I）槲皮素衍生物及其药学上可接受的盐，水合物和溶剂合物，其中R1是氢，苄基或取代的苄基; R2是氢，苄基或取代的苄基，直链或支链（C1-C6）烷基，取代的烷基，芳基，取代的芳基，杂环和取代的杂环，可用于治疗各种疾病，包括癌症，多药耐药性癌症，病毒感染等 本发明还提供了制备式（I）化合物和包含其的药物组合物的方法。
-
公开(公告)号：US20070072876A1
公开(公告)日：2007-03-29
申请号：US11516549
申请日：2006-09-07
申请人： Ravikumar Tadiparthi , Venkatesan Parameswaran , Rajib Barik , Gaddam Reddy , Pawan Aggarwal , Sappanimuthu Thirunavukkarasu , Sriram Rajagopal
发明人： Ravikumar Tadiparthi , Venkatesan Parameswaran , Rajib Barik , Gaddam Reddy , Pawan Aggarwal , Sappanimuthu Thirunavukkarasu , Sriram Rajagopal
IPC分类号： A61K31/513 , C07D239/42 , A61K31/505
CPC分类号： C07D239/38 , C07D239/46 , C07D239/47 , C07D239/48 , C07D401/04
摘要： The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
摘要翻译： 本发明涉及通式（I）的新化合物，其衍生物，其类似物，其互变异构形式，其立体异构体，其多晶型物，它们的水合物，它们的溶剂化物，其药学上可接受的盐和组合物，其代谢物和前药。 本发明更具体地涉及通式（I）的新型嘧啶甲酰胺。 还包括预防或治疗疼痛障碍，免疫疾病，炎症，类风湿性关节炎的方法; 骨质疏松症 多发性骨髓瘤 葡萄膜炎 急性和慢性粒细胞白血病; 缺血性心脏病; 动脉粥样硬化 癌症; 缺血诱导的细胞损伤; 胰腺β细胞破坏; 骨关节炎 类风湿性脊柱炎; 痛风性关节炎 炎症性肠病; 成人呼吸窘迫综合征（ARDS）; 银屑病; 克罗恩病; 过敏性鼻炎; 溃疡性结肠炎 过敏反应 接触性皮炎; 肌肉退化; 恶病质 哮喘; 骨吸收疾病; 缺血再灌注损伤; 脑外伤; 多发性硬化症 败血症 败血性休克 中毒性休克综合征; 发热和由于哺乳动物感染引起的肌痛，包括给予有效量的如上所述的式（I）化合物。
-
公开(公告)号：US07101873B2
公开(公告)日：2006-09-05
申请号：US10409153
申请日：2003-04-09
IPC分类号： A61K31/54
CPC分类号： C07D239/54
摘要： Pyrimidinedione derivatives of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them are useful for the treatment of inflammation and immunological diseases
摘要翻译： 通式（I）的嘧啶二酮衍生物，其衍生物，类似物，互变异构体形式，立体异构体，多晶型物，水合物，溶剂合物，药学上可接受的盐和含有它们的药学上可接受的组合物可用于治疗炎症和免疫疾病
-
公开(公告)号：US07399760B2
公开(公告)日：2008-07-15
申请号：US11414229
申请日：2006-05-01
IPC分类号： A61K31/54
CPC分类号： C07D239/54
摘要： Pyrimidinedione derivatives of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them are useful for the treatment of inflammation and immunological diseases.
摘要翻译： 通式（I）的嘧啶二酮衍生物，其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂化物，药学上可接受的盐和含有它们的药学上可接受的组合物可用于治疗炎症和免疫疾病。
-
公开(公告)号：US07365069B2
公开(公告)日：2008-04-29
申请号：US10827368
申请日：2004-04-20
申请人： Shiv Kumar Agarwal , Ravikumar Tadiparthi , Pawan Aggarwal , Savithiri Shivakumar , Debendranath Dey , Biswajit Nag
发明人： Shiv Kumar Agarwal , Ravikumar Tadiparthi , Pawan Aggarwal , Savithiri Shivakumar , Debendranath Dey , Biswajit Nag
IPC分类号： C07D239/36 , A61K31/513
CPC分类号： C07D239/36 , C07C69/738 , C07C257/18 , C07C317/44 , C07C317/48 , C07C317/50 , C07C323/42 , C07C323/44 , C07C323/62 , C07C327/48 , C07C327/58 , C07D239/48 , C07D239/54 , C07D239/56 , C07D265/06
摘要： The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly novel pyrimidones of the general formula (I)
摘要翻译： 本发明涉及通式（I）的新型嘧啶，它们的衍生物，它们的类似物，它们的互变异构形式，它们的立体异构体，它们的多晶形物，它们的水合物，它们的溶剂化物，它们的药学上可接受的盐和含有它们的药学上可接受的组合物。 本发明更具体地是通式（I）的新颖的嘧啶酮，
-
公开(公告)号：US20060194799A1
公开(公告)日：2006-08-31
申请号：US11414229
申请日：2006-05-01
IPC分类号： C07D413/12 , A61K31/54 , A61K31/655
CPC分类号： C07D239/54
摘要： Pyrimidinedione derivatives of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them are useful for the treatment of inflammation and immunological diseases.
摘要翻译： 通式（I）的嘧啶二酮衍生物，其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂化物，药学上可接受的盐和含有它们的药学上可接受的组合物可用于治疗炎症和免疫疾病。
-
公开(公告)号：US20050107413A1
公开(公告)日：2005-05-19
申请号：US10469647
申请日：2003-07-21
IPC分类号： C07D239/30 , A61K31/505 , A61K31/513 , A61P1/04 , A61P1/18 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P17/00 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/06 , A61P19/10 , A61P21/00 , A61P25/00 , A61P29/00 , A61P29/02 , A61P31/00 , A61P31/16 , A61P31/18 , A61P31/22 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/08 , A61P43/00 , C07D239/34 , C07D239/36 , C07D239/38 , C07D239/42 , C07D239/46 , C07D239/48 , C07D239/56
CPC分类号： C07D239/30 , C07D239/36 , C07D239/38 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/56
摘要： The present invention relates to novel derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel pyrimidine derivatives of the general formula (I).
摘要翻译： 本发明涉及通式（I）的新衍生物，其衍生物，其类似物，其互变异构形式，它们的立体异构体，其多晶型物，它们的水合物，它们的溶剂化物，其药学上可接受的盐和含有它们的药学上可接受的组合物。 本发明更具体地提供了通式（I）的新型嘧啶衍生物。
-
公开(公告)号：US10467560B2
公开(公告)日：2019-11-05
申请号：US12894624
申请日：2010-09-30
申请人： Joylee E Kohler , Pawan Aggarwal , Kedar Swadi
发明人： Joylee E Kohler , Pawan Aggarwal , Kedar Swadi
摘要： Embodiments of the present invention generally relate to a system and method for adaptively assigning multiple contacts to an agent determined by that agent's current metrics data or effectiveness measure. In one embodiment, there is provided a method for adaptively assigning multiple contacts to an agent in a contact center, comprising providing a reporting engine containing an agent's metrics; providing an assignment engine for assigning multiple contacts to the agent based upon the agent's metrics received from the reporting engine; storing each contact being served by the agent with at least one agent metrics element to be measured by the reporting engine; updating the agent's metrics in the reporting engine based upon the measured at least one metrics element; comparing the agent's updated metrics with stored target metrics; and assigning multiple contacts to the agent when the agent's metrics is within the target metrics.
-
公开(公告)号：US07759350B2
公开(公告)日：2010-07-20
申请号：US11516549
申请日：2006-09-07
申请人： Ravikumar Tadipartiii , Venkatesan Parameswaran , Rajib Barik , Gaddam Om Reddy , Pawan Aggarwal , Sappanimuthu Thirunavukkarasu , Sriram Rajagopal
发明人： Ravikumar Tadipartiii , Venkatesan Parameswaran , Rajib Barik , Gaddam Om Reddy , Pawan Aggarwal , Sappanimuthu Thirunavukkarasu , Sriram Rajagopal
IPC分类号： C07D239/28 , A61K31/505
CPC分类号： C07D239/38 , C07D239/46 , C07D239/47 , C07D239/48 , C07D401/04
摘要： The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and compositions, their metabolites and prodrugs thereof. The present invention more particularly relates to novel pyrimidine carboxamides of the general formula (I). Also included is a method of prophylaxis or treatment of a pain disorder, immunological diseases, inflammation, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.
摘要翻译： 本发明涉及通式（I）的新化合物，其衍生物，其类似物，其互变异构形式，其立体异构体，其多晶型物，它们的水合物，它们的溶剂化物，其药学上可接受的盐和组合物，其代谢物和前药。 本发明更具体地涉及通式（I）的新型嘧啶甲酰胺。 还包括预防或治疗疼痛障碍，免疫疾病，炎症，类风湿性关节炎的方法; 骨质疏松症 多发性骨髓瘤 葡萄膜炎 急性和慢性粒细胞白血病; 缺血性心脏病; 动脉粥样硬化 癌症; 缺血诱导的细胞损伤; 胰腺β细胞破坏; 骨关节炎 类风湿性脊柱炎; 痛风性关节炎 炎症性肠病; 成人呼吸窘迫综合征（ARDS）; 银屑病; 克罗恩病; 过敏性鼻炎; 溃疡性结肠炎 过敏反应 接触性皮炎; 肌肉退化; 恶病质 哮喘; 骨吸收疾病; 缺血再灌注损伤; 脑外伤; 多发性硬化症 败血症 败血性休克 中毒性休克综合征; 发热和由于哺乳动物感染引起的肌痛，包括给予有效量的如上所述的式（I）化合物。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.021 秒)
